MONDAY , MAY 23th 2016 |
11:22 AM |
|
Stock: CLRB |
Our Opinion:
SHORT
| |
HEADLINE
Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO

OUR ASSESSMENT
|
|
|
Our objective is to identify stocks that are moving significantly in percentage terms, in a very short period of time.
Research the fundamentals of the company to determine if the recent news justifies the gains reflected in the price. When we are confident the stock increase is not warranted, we release a report.
|
This disclaimer is to be read and fully understood before using any of our website information, following any of our social networking platforms or joining our email list. By using this website or any of our Social Network accounts you agree to the terms of this disclaimer.

|
|